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Testicular germ cell tumors are unique among solid cancers. Historically, this disease
was deadly if progressed beyond the stage I. The implementation of cisplatin-based
chemotherapy regimens has drastically changed the clinical outcome of metastatic
testicular cancer. Several biomarkers were established to refine the prognosis by
International Germ Cell Collaborative Group in 1997. Among these, the most significant
were primary tumor site; metastatic sites, such as non-pulmonary visceral metastases;
and the amplitude of serum tumor markers α-fetoprotein, β-chorionic gonadotropin, and
lactate dehydrogenase. Since then, oncology has experienced discoveries of various
molecular biomarkers to further refine the prognosis and treatment of malignancies.
However, the ability to predict the prognosis and treatment response in germ cell tumors
did not improve for many years. Clinical trials with novel targeting agents that were
conducted in refractory germ cell tumor patients have proven to have negative outcomes.
With the recent advances and developments, novel biomarkers emerge in the field of
germ cell tumor oncology. This review article aims to summarize the current knowledge
in the research of novel prognostic biomarkers in testicular germ cell tumors.
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INTRODUCTION
Testicular germ cell tumors (GCT) are unique in terms of molecular landscape, pathogenesis,
clinical presentation, and response to chemotherapy (1). The exceptional position of GCT among
the solid cancers can be perhaps attributed to their developmental origin in primordial germ
cells. While the cure rate of patients with metastatic disease exceeds 80% (2), the ones failing
the initial and salvage chemotherapy die of their disease in young age. About 40–80% of patients
with relapsed GCT fail the salvage chemotherapy, resulting in the loss of 35 years of life on
average (3–5). The utility of biomarkers to risk-stratify the treatment is well-established in GCT.
Markers of the risk of relapse in the stage I disease, such as tumor size of >4 cm and rete testis
invasion for seminoma, and lymphovascular invasion and predominance of embryonal carcinoma
for non-seminoma, are currently used to risk-stratify the patients for surveillance or adjuvant
treatment (6–9). International Germ Cell Cancer Collaborative Group (IGCCCG) presented the
risk-stratification model for metastatic disease in 1997 using biomarkers such as primary tumor
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site, metastatic sites, the amplitude of serum α-fetoprotein (AFP),
β-chorionic gonadotropin (HCG), and lactate dehydrogenase
(LDH) (10). These criteria are based on patient series collected
retrospectively between 1975 and 1990. Since then, the treatment
strategy was optimized, and outcomes improved as reported from
high volume centers (2, 11, 12). Further refining of IGCCCG
criteria is expected soon in the updated version of the IGCCCG
classification (Figure 1).
New reports on novel biomarkers are scarce since the
introduction of the commonly used GCT biomarkers over three
decades ago. The utility of novel molecular biomarkers in
numerous solid cancers has significantly moved the advancement
of oncology. Malignancies, such as lung cancer, melanoma, and
kidney cancer, were previously considered untreatable, but now
the array of molecular markers renders these diseases treatable
with targeting agents ultimately prolonging lives of patients with
incurable cancer (13, 14). Such advancement seemingly evades
testicular GCT due to lack of known drugable targets. While the
overall cure rate of GCT patients is excellent, ones refractory
to standard chemotherapy lack the possibility to receive novel
effective treatments and their prognosis is dismal. The biology
of GCTs is unique, therefore translational research to uncover
the biological implications is essential in the pursuit of treatment
targets that may improve the prognosis of platinum refractory
GCT patients. This article aims to summarize the current
knowledge on the emerging biomarkers in GCT.
BRIEF OVERVIEW OF MOLECULAR
LANDSCAPE IN TESTICULAR GERM CELL
TUMORS
Understanding why we lack a significant predictive biomarker
in GCT requires a look into their molecular landscape and
developmental origins. The origin of GCT particularly show how
different their biology is compared to other solid cancers. The
data from The Cancer Genome Atlas (TCGA) show a rather
quiet mutational landscape in GCT compared to other solid
tumors (15).
Several genomewide studies suggested driver mutations in
only three genes (KIT, KRAS, andNRAS) in 4–31% of seminoma,
and up to 14% of non-seminoma patients (16–19). Since these
mutations were discovered in a minority of patients, a single
universal mutational driver is not a feasible explanation in the
development of GCT. Rather, a polygenic nature of testicular
cancer was proposed, where the number of low frequency
susceptibility genes (up to 50 risk loci reported until present)
seems to produce an increased risk for the GCT (20). A recent
paper by Shen et al. conducted a comprehensive molecular
characterization of available tissue from 137 GCT patients. The
authors confirmed findings of previously known mutated genes
(KIT, KRAS, and NRAS) and provided yet additional evidence
of low mutational burden with frequency of 0.5 mutations per
megabase (15).
Despite the unimpressive mutational characteristics, GCT
share a unique epigenetic landscape. GCT subtypes are an
example of developmental processes from pluripotent embryonic
stem cells toward certain degrees of differentiation to somatic
tissues. The mapping of GCT methylome is perhaps the
most comprehensively assessed to this date. The global
DNA-methylation status clearly correlates with the state of
differentiation in the histological GCT subtypes. Seminomas,
which show the lowest degree of differentiation are typically
unmethylated or severely hypomethylated tumors. Embryonal
carcinomas show low to intermediate levels of global DNA
methylation and well-differentiated yolk sac tumors, and
teratomas show high levels of DNA methylation. Thus, the
significant histological variability complies with the epigenetic
heterogeneity. These findings also comply with the epigenetic
landscape of healthy tissues where differentiated somatic tissues
show hypermethylated pattern (21–23). Non-CpG methylation,
acetylation, and methylation of histones are also mechanisms
likely involved in the biology of GCT. They are, however, poorly
understood in present time. microRNA (miR) signaling research
on the other hand seems to provide promising results toward
increasing the knowledge aboutmolecular biology of GCT.While
the miR signaling is generally complex and is a subject of
innumerous interactions, the clusters of miR discussed later in
this paper provide a significant biomarker potency to further
refine the management of GCT.
The unique germline origin of GCT is underlined with the
overexpression of markers of pluripotency such as NANOG,
OCT3/4 or a tissue stem cell factor KIT and its’ ligand
(24–30). The expressions of these markers have been linked
to epigenetic regulation with DNA methylation and histone
acetylation (30–34).
EMERGING BIOMARKERS IN GERM CELL
TUMORS
Clinical Biomarkers
IGCCCG vol. 2 will bring a long-awaited update for
risk stratification of treatment of GCT based on clinical
characteristics. The advent of clinical biomarkers is rather slow
since the original publication of the IGCCCG criteria. Several
other risk assessment criteria were proposed that considered
a more detailed look into clinical characteristics in GCT
patients. Adra et al. published results of their retrospective
analysis of 273 patients with a poor risk disease treated at
Indiana University (35). Primary mediastinal non-seminoma
(PMNSGCT), brain metastases and increasing age were
significant predictors of mortality (HR = 4.63, 3.30, and
1.06, respectively). Multiple criteria for a poor risk disease
carried a significantly worse prognosis compared to a single
criterion (35).
Necchi et al. proposed an improved model for intermediate
risk patients in the two-institutional initiative using PMNSGCT,
brain metastases, pulmonary metastases, and age at diagnosis as
risk factors. According to the results, a number of intermediate
risk patients would suffice from treatment with BEPx3, whereas
the current standard remains BEPx4 (11). While the refining
of prognosis based on clinical criteria may have reached
its limits, authors from Memorial Sloan Kettering Cancer
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FIGURE 1 | The landmarks of prognostic biomarkers in germ cell tumors. IGCCCG, International Germ Cell Cancer Consensus Group; RTI, rete testis invasion; LVI,
lymphovascular invasion; EC, embryonal carcinoma; miR, microRNA; TSmiR, targeted serum microRNA test.
Center have proposed a novel prognostic marker based on a
marker decline after the first course of chemotherapy (36).
Patients who had unfavorable (slower) marker decline after
the initiation if chemotherapy had reportedly worse outcomes
compared to patients with favorable marker decline (72 vs.
95% for 2-year overall survival; P < 0.01) (36). These
findings were subsequently replicated in independent studies
(37, 38).
Furthermore, the prognostic significance of tumor marker
decline was reported also in patients with relapse (39–41). Fizazi
et al. conducted a randomized phase III study in poor risk GCT.
Patients receiving first cycle of BEP had an assessment of serum
markers prior to second cycle and ones with an unfavorable
decline were randomized to receive either remaining three cycles
of standard BEP or dose-intensified chemotherapy regimen.
Based on this biomarker-based strategy, a significant advantage
was reported for 5-year progression-free survival (PFS) (60 vs.
48%, P = 0.037), but not for 5-year overall survival (OS) (70 vs.
61%, P = 0.012) (42, 43). Interestingly, in cases of progression,
patients from this study relapsed predominantly in brain (54% of
all relapses) (44).
Molecular Biomarkers From
Immunohistochemistry Studies
Immunohistochemistry studies have started to emerge in recent
years to supplement the clinical biomarkers in predicting
the prognosis of GCT. The higher expression of DNA
repair enzyme poly (ADP-ribose) polymerase (PARP) was
reported in GCT tissue compared to normal testicular tissue.
However, no association with clinical characteristics nor
the survival difference was reported in regard to levels of
expression (45).
Kalavska et al. published two studies examining the prognostic
value of carbonic anhydrase nine assessed from plasma and
from tumor tissue (46, 47). Levels of this marker of hypoxia
and aggressive tumor behavior correlated in plasma and in
tumor tissue. High expression in tumor was associated with
shorter PFS; however, the clinically more useful utility of
plasmatic assessment failed to be prognostic in GCT (46,
47). The hepatocyte growth factor (HGF) and its receptor c-
MET were investigated by immunohistochemistry in tumors
and in cell-line culture. c-MET is a known proto-oncogene
involved in tumor progression and metastasis. Authors of this
study reported an abundant immunohistochemical expression in
both seminomas and non-seminomas, particularly in epithelial
structures of well-differentiated subtypes such as teratomas,
yolk sac tumors, and choriocarcinomas. Upon the activation
of c-MET in an NT2 cell line (embryonal carcinoma), the
cells acquired a more robust ability to proliferate, migrate,
and invade. This may create the rationale for further research;
however, the clinical significance of this finding is currently
unknown (48).
Immune-Related Biomarkers
The discovery of novel immune-related biomarkers,
programmed-death receptor and its ligand (PD-1
and PD-L1) in various cancers, led to a confirmation
of active PD-1/PD-L1 signaling also in GCT by
Fankhauser et al. (49). The authors conducted an
immunohistochemistry study and showed a frequent
PD-L1 expression in 479 GCT tissue samples. Both
seminomas and non-seminomas exhibited a significant
expression of PD-L1 (in 73% and 64% of patients,
respectively) (49).
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Another research team led by Mardiak et al. performed
a similar study and scored the PD-L1 expression semi-
quantitatively with multiplicative quick score. The scores were
correlated with clinical outcome. Patients with low levels of PD-
L1 expression had significantly better PFS (HR= 0.40; P= 0.008)
and OS (HR= 0.43; P= 0.040) (50). Furthermore, the expression
of PD-L1 on tumor infiltrating lymphocytes (TIL) proved to
be highly predictive of outcome in a reverse manner. Patients
with high PD-L1 expression on TIL had significantly better
prognosis than patients with low PD-L1 TIL (51). The prognostic
significance of TIL was earlier reported by Bols et al., who
also performed the phenotyping of immune-cell infiltrates (52).
However, the abundant expression of PD-L1 does not seem to
be predictive of response to treatment with immune-checkpoint
inhibitors.
A phase II study with anti-PD1 agent pembrolizumab
provided data about insufficient anti-tumor activity in refractory
patients with GCT (53). While several case reports documented
possible responses to immune-check point inhibitor, these are
likely due to concomitant treatment with chemotherapy (54–
56). Another phase II study with anti-PD-L1 agent avelumab is
currently ongoing, which will shed more light on single agent
immunotherapy in refractory GCT (NCT03403777).
Currently, there is a level of uncertainty in predicting response
according to PD-L1 expression levels. While several cancer types
have proven to be sensitive to PD-1/PD-L1 blockade based on
PD-L1 expression, PD-L1 negative tumors were described to
respond to such treatment as well. On the other hand, the
expression of PD-L1 in tumor and TIL in GCT signifies a
vivid immunogenic microenvironment but fails to respond to
immunotherapy according to our present knowledge. As such,
PD-1/PD-L1 axis seems to be only a part of the involved immune
machinery and we are lacking a deeper understanding. Shen
et al. recently published findings of comprehensive molecular
characterization of GCT and did not discover a significant
neoantigen signal in GCT, thus the insufficient activity of
immune check-point inhibitors in GCT may be partly explained
by this fact and the presence of very low mutational load (15).
Two independent studies published simultaneously
examined the role of a simple marker of proinflammatory
macroenvironment, a systemic-immune infiltration index (SII)
(57, 58). SII is calculated from total counts of neutrophils,
lymphocytes, and platelets. Fankhauser et al. reported numerous
markers associated with poor prognosis in GCT, including
low hemoglobin and albumin, high leukocytes, neutrophils,
CRP, neutrophil to lymphocyte ratio, and SII (58). At the
same time, our study showed that high SII was associated with
poor prognosis in two independent cohorts of GCT patients.
We also evaluated a combined prognostic value of SII and
PD-L1 expression on TIL. As a result, we identified patients
who never experienced death nor a relapse if they exhibited
low SII and high PD-L1 on TIL (57). Both studies reported
the prognostic significance of SII being independent from the
standard IGCCCG risk criteria. SII can be easily calculated
from complete blood count performed prior to treatment and
offers a simple tool to predict outcome in metastatic GCT. Poor
prognosis in patients exhibiting high levels of SII also suggests
that proinflammatory pathways likely unleashed by an aggressive
tumor microenvironment may point to an unsuccessful struggle
of the host immune system to overcome the tumor growth.
Furthermore, signaling of proinflammatory cytokines, such as
IFN-α2, IL-2Rα, or IL-16, was reported to be associated with
poor risk clinical characteristics and inferior survival in GCT
patients (59).
Nilius et al. recently reported that high expression of β-1,4-
galactosyltransferase-I (B4GALT1) in peripheral T-lymphocytes
is a marker of lower risk of relapse in GCT patients treated
with salvage high-dose chemotherapy and peripheral stem cell
transplant (HR = 0.66; 95% CI 0.45–0.97; P = 0.02) (60). T-cells
were collected before the high-dose chemotherapy using the non-
myeloablative chemotherapy and granulocyte growth factor (60).
B4GALT1 is important for interaction and adhesion of immune
cells and its role in disease control in stage I lung cancer has been
established (61). This study supported their hypothesis of the
importance of activated peripheral T cells in in vitro experiments
by lectin stimulation of mononuclear cells with Concavalin A.
As a result, B4GALT1 was upregulated, particularly in CD4+
cells and an antiinflammatory cytokine IL10 was significantly
expressed. Interestingly, higher levels of IL10 from patient T
cells were also associated with better outcome in GCT (60).
Activated T cells, thus, seem to play an important role in cancer
control.
Liquid Biopsies and Epigenetic Biomarkers
Sensitive and specific biomarkers indicating the presence of
cancer that are assessed from peripheral blood represent
an attractive and convenient approach in the diagnosis
malignancies. Researchers recently published an array of articles
showing that certain clusters of miR are highly informative
of the presence of viable cancer in GCT patients (62–70).
Serum examination for miR371-373 showed sensitivity of 98–
100%, exceeding the sensitivity of the commonly used serum
tumor markers AFP and HCG (71, 72). The targeted serum
miRNA test (TSmiR) was developed and it seems to be very
effective in predicting viable GCT after orchiectomy in clinical
stage I patients or after chemotherapy in metastatic disease
(72). The clinical utility of the TSmiR test is therefore very
promising and clinicians may be expecting this novel biomarker
to be implemented in the common practice in the near future
(73). One possible utility of these highly sensitive miRNAs
seems to be predicting the presence of a microscopic disease
in clinical stage I GCTs. As such, these are likely to change
the outlook over adjuvant treatment vs. surveillance. Another
valuable input would be predicting the presence of viable
cancer in post-chemotherapy residual masses, thus refining
the need to perform often difficult surgeries in this setting.
However, TSmiR does not identify teratoma components which
still represent a diagnostic dilemma in the residual disease.
Establishing the novel clinical practice stems from our ability
to validate the utility of TSmiR in larger prospective cohorts of
patients.
Majewski et al. assessed five patients with stage I seminoma
and evaluated a possible role of liquid biopsy in identifying
the presence of the tumor. The study showed promising
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results and identified candidate genes in whole blood prior
to orchiectomy. This series is, however, too small to draw
any conclusions and a larger study is suggested for validation
(74).
A global DNA hypermethylation was proposed as one
of the acting mechanisms in cisplatin resistance, the most
frustrating challenge for oncologists treating GCT patients.
In vitro epigenetic studies suggested that treatment with
DNA demethylating agents may restore the sensitivity to
cisplatin (75–77). In a study by Beyrouthy et al., a GCT cell-
line treated with decitabine was resensitized to cisplatin
(78). Based on these findings, Albany et al. performed
a series of experiments in cell-line culture and patient-
derived xenograft mouse model using a second-generation
inhibitor of DNA-methyltransferase guadecitabine. Upon
treatment of platinum resistant xenografts, a significant
growth inhibition and even complete tumor regression was
registered (79). An ongoing phase I trial using guadecitabine
in combination with cisplatin in refractory GCT will shed
more light on clinical significance of these promising findings
(NCT02429466).
CONCLUSION
The investigation for biomarkers in testicular cancer has been
insufficient in the past, but with emerging data our knowledge
it is built up with an increasing consistency. Such consistency is
essential to generate experimental data and perform laboratory
research which will ultimately lead to development of novel drugs
with a promise to overcome the resistance to cisplatin.
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